

**CERTIFICATE OF MAILING**

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

James Epperson
Type or print name

James Epperson
Signature

January 8, 2004
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

YU ET AL.

APPLICATION NO: 10/643,411

FILED: AUGUST 19, 2003

FOR: HETEROCYCLIC SUBSTITUTED 2-METHYL-BENZIMIDAZOLE
ANTIVIRAL AGENTS

Mail Stop DD
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants believe this paper is being filed before the mailing date of a first Office Action on the merits, and so under 37 C.F.R. §1.97(b)(3) no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-3880.


In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

The listed references are of record in parent Application No. 09/994,012 filed November 16, 2001, and copies are available therein. However, applicants are willing to send copies of any or all of these references at the Examiner's request.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,


Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000
203-677-6974


James Epperson
Agent for Applicants
Reg. No. 52,867

Date: 1/8/2003

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
CT-2645A DIV1
APPLICATION NO.
10/643,411
APPLICANT
YU ET AL.
FILING DATE
August 19, 2003

Group --

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA	4,324,794	4/13/82	R. R. Tidwell, et al			
	AB	5,256,668	10/26/93	K.-H. L. Hsu, et al			
	AC	3,394,141	7/23/68	F. Sparatore			
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AJ	EP 058146A1	8/18/82	US Patent 4,525,358 English Equivalent			<input type="checkbox"/>	<input type="checkbox"/>
	AK	AU-A-14,704	12/22/98	US Patent 5,852,015 English Equivalent			<input type="checkbox"/>	<input type="checkbox"/>
	AL	WO 01/36395	5/25/01	PCT Patent Application			<input type="checkbox"/>	<input type="checkbox"/>
	AM	WO 00/38508	7/6/00	PCT Patent Application			<input type="checkbox"/>	<input type="checkbox"/>
	AN	WO 01/00611	1/4/01	PCT Patent Application			<input type="checkbox"/>	<input type="checkbox"/>
	AO	WO 01/00612	1/4/01	PCT Patent Application			<input type="checkbox"/>	<input type="checkbox"/>
	AP	WO 01/00615	1/4/01	PCT Patent Application			<input type="checkbox"/>	<input type="checkbox"/>
	AQ	WO 00/04900	2/3/00	PCT Patent Application			<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AR	E. J. Dubovi, et al, ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 19(4), pp. 649-656, 1981
	AS	P. R. Wyde, et al, ANTIVIRAL RESEARCH, 38, pp. 31-42, 1998
	AT	F. Pagani, et al, BOLL. CHIM. FARM., 104, pp. 427-431, 1965

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.


FORM PTO-1449
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
CT-2645A DIV1
APPLICATION NO.
10/643,411
APPLICANT
YU ET AL.
FILING DATE
August 19, 2003

Group --



OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AU	G. Paglietti, et al, IL. FARMACO-ED. SC., 30 , pp. 505-511, 1975
AV	S. Shigeta, et al, ANTIVIRAL CHEMISTRY & CHEMOTHERAPY, 3(3) , pp. 171-177, 1992
AW	W. R. Roderick, et al, J. MED. CHEM., 15(6) , pp. 655-658, 1972
AX	B. Cakir, et al, GAZI ECZACILIK FAK. DER., 5(1) , pp. 71-77, 1988
AY	H. R. Howard, et al, EUR. J. MED. CHEM., 27 , pp. 779-789, 1992
AZ	F. Sparatore, et al, IL FARMACO ED. SCI., 33 , pp. 901-923, 1978
BA	JAMA, 277(1) , pp. 12-13, 1997
BB	E. De Clercq, INT. J. ANTIMICROBIAL AGENTS, 7 , pp. 193-202, 1996
BC	R. R. Tidwell, et al, J. MED. CHEM., 26 , pp. 294-298, 1983
BD	
BE	
BF	
BG	
BH	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.